X

Trial Profile

Trabectedin Combined With Durvalumab (MEDI4736) in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas. A Phase Ib Study

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 07 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Trabectedin (Primary)
Indications Adenocarcinoma; Carcinoma; Ovarian cancer; Soft tissue sarcoma
Focus Adverse reactions; Therapeutic Use
Acronyms TRAMUNE

Most Recent Events

29 Dec 2021 Status changed from active, no longer recruiting to completed, according to results published in the Clinical Cancer Research.
29 Dec 2021 Results published in the Clinical Cancer Research
04 May 2021 Planned End Date changed from 5 May 2021 to 1 Dec 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com